It is always a delight to hear from those in the party opposite on this, because of their childlike wonder and astonishment as they discover new features and issues in a system that they designed and have overseen for quite some time. I am happy to write to the noble Earl with more details on that scenario. We are considering all the ways to ensure that we have an affordable welfare bill, including making sure that we have efficiencies across the board.

Emerging evidence from local services suggests Single Point of Access (SPoA) supports patients to receive rapid specialist assessments and a clear next step for their treatment by embedding a timely specialist clinical review at the start of the pathway, including for cardiology and cardiothoracic referrals. The model helps patients access the right clinic, diagnostic service, or care setting the first time, and averts the need for them to join lengthy hospital waiting lists unnecessarily, ensuring capacity is available for patients that need specialist care. We are also supporting the development and evaluation of streamlined referral pathways, including SPoA and rapid access valve assessment models, as part of wider cardiovascular pathway improvement work.

As set out in the Medium Term Planning Framework all providers are, from April 2026, expected to prioritise Advice and Guidance (A&G) requests for at least 10 specialties, selected locally for the greatest overall benefit, ahead of ensuring all appropriate requests and referrals flow through a SPoA model from October 2026. Providers are expected to begin implementation of SPoA by prioritising the 10 specialties selected for A&G. The specialties selected by providers could include cardiology or cardiothoracic surgery, which would cover care for heart valve disease.

Technical guidance has been issued to providers outlining expectations to support SPoA implementation. There are currently no specific plans to mandate SPoA in national service specifications. However, we are developing a new Cardiovascular Disease Modern Service Framework, due to be published shortly, which will support the adoption of evidence‑based pathway improvements.

Emerging evidence from local services suggests Single Point of Access (SPoA) supports patients to receive rapid specialist assessments and a clear next step for their treatment by embedding a timely specialist clinical review at the start of the pathway, including for cardiology and cardiothoracic referrals. The model helps patients access the right clinic, diagnostic service, or care setting the first time, and averts the need for them to join lengthy hospital waiting lists unnecessarily, ensuring capacity is available for patients that need specialist care. We are also supporting the development and evaluation of streamlined referral pathways, including SPoA and rapid access valve assessment models, as part of wider cardiovascular pathway improvement work.

As set out in the Medium Term Planning Framework all providers are, from April 2026, expected to prioritise Advice and Guidance (A&G) requests for at least 10 specialties, selected locally for the greatest overall benefit, ahead of ensuring all appropriate requests and referrals flow through a SPoA model from October 2026. Providers are expected to begin implementation of SPoA by prioritising the 10 specialties selected for A&G. The specialties selected by providers could include cardiology or cardiothoracic surgery, which would cover care for heart valve disease.

Technical guidance has been issued to providers outlining expectations to support SPoA implementation. There are currently no specific plans to mandate SPoA in national service specifications. However, we are developing a new Cardiovascular Disease Modern Service Framework, due to be published shortly, which will support the adoption of evidence‑based pathway improvements.

Emerging evidence from local services suggests Single Point of Access (SPoA) supports patients to receive rapid specialist assessments and a clear next step for their treatment by embedding a timely specialist clinical review at the start of the pathway, including for cardiology and cardiothoracic referrals. The model helps patients access the right clinic, diagnostic service, or care setting the first time, and averts the need for them to join lengthy hospital waiting lists unnecessarily, ensuring capacity is available for patients that need specialist care. We are also supporting the development and evaluation of streamlined referral pathways, including SPoA and rapid access valve assessment models, as part of wider cardiovascular pathway improvement work.

As set out in the Medium Term Planning Framework all providers are, from April 2026, expected to prioritise Advice and Guidance (A&G) requests for at least 10 specialties, selected locally for the greatest overall benefit, ahead of ensuring all appropriate requests and referrals flow through a SPoA model from October 2026. Providers are expected to begin implementation of SPoA by prioritising the 10 specialties selected for A&G. The specialties selected by providers could include cardiology or cardiothoracic surgery, which would cover care for heart valve disease.

Technical guidance has been issued to providers outlining expectations to support SPoA implementation. There are currently no specific plans to mandate SPoA in national service specifications. However, we are developing a new Cardiovascular Disease Modern Service Framework, due to be published shortly, which will support the adoption of evidence‑based pathway improvements.

The Government recognises the benefits that emerging innovative technologies such as digital breast tomosynthesis (DBT) may bring to the NHS Breast Screening Programme. At present, DBT is an optional tool in the assessment of screen detected soft tissue breast abnormalities following mammography. Digital mammography, which offers high quality images, currently remains the primary screening tool for the programme as recommended by the UK National Screening Committee (UK NSC).

In 2025, the UK NSC, who advise the Government on all screening matters, set up a working group of breast cancer screening experts to help it consider new and emerging evidence and developments that could further improve the United Kingdom breast screening programmes. This includes exploring modalities such as DBT in addition to other tests and technologies, to detect breast cancer in women with dense breast tissue.

If, following this work, the UK NSC makes a recommendation regarding DBT, my Rt Hon. Friend, the Secretary of State for Health and Social Care, would be asked to make a decision on whether to accept the recommendation, alongside wider policy and operational advice.

The Government recognises the benefits that emerging innovative technologies such as digital breast tomosynthesis (DBT) may bring to the NHS Breast Screening Programme. At present, DBT is an optional tool in the assessment of screen detected soft tissue breast abnormalities following mammography. Digital mammography, which offers high quality images, currently remains the primary screening tool for the programme as recommended by the UK National Screening Committee (UK NSC).

In 2025, the UK NSC, who advise the Government on all screening matters, set up a working group of breast cancer screening experts to help it consider new and emerging evidence and developments that could further improve the United Kingdom breast screening programmes. This includes exploring modalities such as DBT in addition to other tests and technologies, to detect breast cancer in women with dense breast tissue.

If, following this work, the UK NSC makes a recommendation regarding DBT, my Rt Hon. Friend, the Secretary of State for Health and Social Care, would be asked to make a decision on whether to accept the recommendation, alongside wider policy and operational advice.

The Government recognises the benefits that emerging innovative technologies such as digital breast tomosynthesis (DBT) may bring to the NHS Breast Screening Programme. At present, DBT is an optional tool in the assessment of screen detected soft tissue breast abnormalities following mammography. Digital mammography, which offers high quality images, currently remains the primary screening tool for the programme as recommended by the UK National Screening Committee (UK NSC).

In 2025, the UK NSC, who advise the Government on all screening matters, set up a working group of breast cancer screening experts to help it consider new and emerging evidence and developments that could further improve the United Kingdom breast screening programmes. This includes exploring modalities such as DBT in addition to other tests and technologies, to detect breast cancer in women with dense breast tissue.

If, following this work, the UK NSC makes a recommendation regarding DBT, my Rt Hon. Friend, the Secretary of State for Health and Social Care, would be asked to make a decision on whether to accept the recommendation, alongside wider policy and operational advice.

On 24 November, the Department announced its commitment to consult on the powers available to different professionals in different situations and settings, in particular, but not limited to, the operation of the emergency powers in sections 135 and 136. The consultation will seek views on powers and joint working approaches to ensure that health and social care professionals and police have the appropriate powers to act in order to prevent people harming themselves and others when in a mental health crisis.

The Department also set out plans to work closely with a range of stakeholders to shape the scope of that consultation. Officials at the Department of Health and Social Care have started engagement with Home Office officials and stakeholders from the police, health, and social care to consider the options to consult on that support better outcomes for patients and services, and we will set out further detail on the timing of the consultation in due course.